RedHill Biopharma Ltd. (RDHL)


-0.03 (-3.66%)
Symbol RDHL
Price $0.915
Beta 1.930
Volume Avg. 2.20M
Market Cap 48.733M
Shares () -
52 Week Range 0.62-11.18
1y Target Est -
DCF Unlevered RDHL DCF ->
DCF Levered RDHL LDCF ->
ROE -379.42% Strong Sell
ROA -53.95% Strong Sell
Operating Margin -
Debt / Equity 1941.55% Strong Buy
P/E -
P/B 4.82 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest RDHL news

Mr. Dror Ben-Asher
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.